CIBC World Markets Inc. bought a new position in Perrigo Company (NYSE:PRGO) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 16,908 shares of the company’s stock, valued at approximately $1,277,000.
A number of other hedge funds have also recently modified their holdings of PRGO. BlackRock Inc. lifted its position in Perrigo by 3,825.1% in the first quarter. BlackRock Inc. now owns 12,154,494 shares of the company’s stock worth $806,936,000 after purchasing an additional 11,844,832 shares during the period. Aberdeen Asset Management PLC UK lifted its position in Perrigo by 65.2% in the first quarter. Aberdeen Asset Management PLC UK now owns 3,028,619 shares of the company’s stock worth $201,070,000 after purchasing an additional 1,195,526 shares during the period. Vanguard Group Inc. lifted its position in Perrigo by 4.5% in the first quarter. Vanguard Group Inc. now owns 14,574,768 shares of the company’s stock worth $967,619,000 after purchasing an additional 633,343 shares during the period. North Tide Capital LLC bought a new position in Perrigo in the first quarter worth $39,834,000. Finally, State Street Corp lifted its position in Perrigo by 8.5% in the first quarter. State Street Corp now owns 6,644,799 shares of the company’s stock worth $441,153,000 after purchasing an additional 520,967 shares during the period. 80.36% of the stock is owned by hedge funds and other institutional investors.
Shares of Perrigo Company (NYSE PRGO) opened at 88.89 on Friday. Perrigo Company has a 12 month low of $63.68 and a 12 month high of $99.14. The firm’s market capitalization is $12.68 billion. The company has a 50-day moving average price of $77.25 and a 200-day moving average price of $73.22.
Perrigo (NYSE:PRGO) last posted its earnings results on Thursday, August 10th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $0.94 by $0.28. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.18 billion. Perrigo had a positive return on equity of 11.55% and a negative net margin of 51.04%. The business’s quarterly revenue was down 7.7% on a year-over-year basis. During the same period last year, the company earned $1.93 earnings per share. Equities analysts forecast that Perrigo Company will post $4.58 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Friday, August 25th were given a dividend of $0.16 per share. The ex-dividend date was Wednesday, August 23rd. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.72%. Perrigo’s dividend payout ratio (DPR) is -3.51%.
A number of research analysts have issued reports on the company. Royal Bank Of Canada reissued a “sell” rating and set a $64.00 price objective on shares of Perrigo in a report on Wednesday. Wells Fargo & Company reissued a “market perform” rating and set a $77.00 price objective on shares of Perrigo in a report on Tuesday, August 15th. Stifel Nicolaus reissued a “hold” rating on shares of Perrigo in a report on Friday, August 11th. Canaccord Genuity set a $80.00 price objective on Perrigo and gave the company a “buy” rating in a report on Wednesday, May 31st. Finally, Deutsche Bank AG lifted their price objective on Perrigo from $88.00 to $95.00 and gave the company a “buy” rating in a report on Thursday. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating to the stock. Perrigo has a consensus rating of “Hold” and an average price target of $89.36.
COPYRIGHT VIOLATION WARNING: This article was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://transcriptdaily.com/2017/09/15/cibc-world-markets-inc-takes-position-in-perrigo-company-prgo.html.
In related news, EVP Sharon Kochan sold 318 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $81.36, for a total transaction of $25,872.48. Following the completion of the sale, the executive vice president now owns 10,231 shares of the company’s stock, valued at $832,394.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Thomas Farrington sold 616 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $76.90, for a total value of $47,370.40. Following the sale, the executive vice president now directly owns 2,724 shares of the company’s stock, valued at approximately $209,475.60. The disclosure for this sale can be found here. Insiders have sold 6,894 shares of company stock valued at $581,320 over the last 90 days. 6.90% of the stock is owned by corporate insiders.
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company (NYSE:PRGO).
Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.